Avion Wealth’s Keros Therapeutics KROS Stock Holding History

Avion Wealth’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-36	Closed	–	–	1435
2025 Q4	$0	Hold	36	–	–	﹤0.01%	1427
2025 Q3	$0	Hold	36	–	–	﹤0.01%	1395
2025 Q2	$0	Buy	+36	New	+$486	﹤0.01%	1406

Other funds holding KROS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Avion Wealth's KROS Position: Q1 2026 in Review

Avion Wealth sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 36 shares.

Avion Wealth first reported a position in KROS in Q2 2025 and held it in 3 quarters. The position peaked at $0 in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

Avion Wealth reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
Avion Wealth sold 36 Keros Therapeutics shares in Q1 2026.
Avion Wealth first reported a position in Keros Therapeutics in Q2 2025 and held it in 3 quarters.
Avion Wealth's Keros Therapeutics position peaked at $0 in Q4 2025.
151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Avion Wealth's 13F filing for Q1 2026, filed 1 May 2026.